| Document |
Document Title |
|
WO/2021/078698A1 |
Process for making a compound represented by formula (3), comprising the following steps: a) reacting an azide compound with a compound represented by formula (1) to yield compound (2), compound (2) being a compound represented by formul...
|
|
WO/2021/080380A1 |
The present disclosure relates to a method for preparing aryl 2-tetrazol-2-yl ketone of Formula 1a with improved selectivity.
|
|
WO/2021/069927A1 |
The disclosures herein relate to novel compounds of formula (1): (1) and salts thereof, wherein A, X, R1, R2, R3, R4, R10 and R11 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk o...
|
|
WO/2021/068816A1 |
Disclosed are an alkene-containing amide compound and the use of an agriculturally acceptable salt thereof as a herbicide. The compound is as represented by general formula (I): the substituents in general formula I are defined in the de...
|
|
WO/2021/066260A1 |
The present invention relates to functional group-protected diazidoglyoxime, a synthesis method therefor, and a TKX-50 synthesis method using functional group-protected diazidoglyoxime. Insensitive-DAG having improved insensitivity is sy...
|
|
WO/2021/062559A1 |
This disclosure relates to carmabinoid derivatives of Formula (1) wherein R4 or R7 is a carboxamide group, pharmaceutical compositions comprising these compounds and methods of using the carmabinoid derivatives. These compounds are poten...
|
|
WO/2021/039660A1 |
The present specification discloses a method for producing an isocyanate compound. The present invention relates to a method for producing a compound represented by formula (2), wherein in the presence of a water-immiscible solvent and w...
|
|
WO/2021/033530A1 |
This method for producing a radioactive metal complex comprises a step for reacting a radioactive metal with DOTA or a ligand, which is a derivative of DOTA, in a reaction solution to form a radioactive metal complex. The reaction soluti...
|
|
WO/2021/034924A1 |
Featured are trans-cyclooctene and tetrazine compounds. Also provided are methods for evaluating the biodistribution and/or concentration of a biomolecule in a subject.
|
|
WO/2021/028810A1 |
The present invention relates to certain compounds, their use in therapy, as well as to pharmaceutical compositions including said compounds. Specifically, the invention relates to certain compounds and pharmaceutical compositions includ...
|
|
WO/2021/022516A1 |
Disclosed is a Valsartan refinement method, comprising: firstly, reacting Valsartan in water with an alkali or a salt of a strong alkali and a weak acid so as to generate a Valsartan salt; then reacting the Valsartan salt with an acid so...
|
|
WO/2021/020429A1 |
The present invention provides a compound represented by formula (I) or a pharmaceutically acceptable salt thereof which has the effect of antagonizing the LPA1 receptor.
|
|
WO/2021/021120A1 |
A system, software application and method that allows a customer to protect their proprietary database of compounds and substances while utilizing a retrosynthesis software application is disclosed. The customer's proprietary database is...
|
|
WO/2021/019983A1 |
The purpose of the present invention is to react radioactive zirconium at a high reaction rate to synthesize a zirconium complex even using low-concentration DOTA or NOTA. A mixed solution, obtained by finally mixing zirconium dissolved ...
|
|
WO/2021/016392A1 |
Multivalent ligand-targeted active agents, such as detectable agents or therapeutic agents, for the imaging and treatment, respectively, of fibroblast activation protein (FAP)-positive cancer-associated fibroblasts (CAFs) and activated m...
|
|
WO/2021/013969A1 |
The present invention related to compounds of Formula (I): or an agronomically acceptable salt thereof, wherein Q, R2, R3, R4, R5 and R6 are as described herein. The invention further relates to compositions comprising said compounds, to...
|
|
WO/2021/007661A1 |
The current application relates to cannabinoid derivatives of formula (I) and pharmaceutical compositions comprising the same. The cannabinoid derivative can be used for the treatment of diseases associated with cannabinoid receptor such...
|
|
WO/2020/198466A9 |
The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with an adrenergic receptor. In certain embodiments of the methods disclosed herein, the methods include ad...
|
|
WO/2020/254558A1 |
The present disclosure relates to compounds suitable for treating, ameliorating and/or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein can inhibit the ClC...
|
|
WO/2020/252598A1 |
A compound comprising a prostate specific membrane antigen (PSMA)-targeting moiety of the following formula or of a salt or a solvate thereof. R0 is O or S. Each of R1a, R1b and R1c may be –CO2H, –SO2H, –SO3H, –PO2H, or –PO3H2,...
|
|
WO/2020/252662A1 |
The present application relates to a method for refining valsartan, which mainly removes nitrosamine impurities from valsartan. The specific method is: first dissolving valsartan in an organic solvent, washing using an acidic aqueous sol...
|
|
WO/2020/248341A1 |
Provided is a method for preparing valsartan, comprising the step of subjecting a valsartan nitrile group compound (II), an azide compound, a Lewis acid and a phase transfer catalyst to a tetrazole cyclization reaction in a non-hydrophil...
|
|
WO/2020/247819A2 |
Described herein is a compound of Formula I or a pharmaceutically acceptable salt thereof: wherein Ring A R1, R2, a, b, and n are as defined herein. Also described is a method of treating a subject having a disorder in need of treatment,...
|
|
WO/2020/244225A1 |
Disclosed is a preparation method for triphenylchloromethane, comprising the following steps: adding hydrochloric acid or a mixture of hydrochloric acid and Lewis acid to a mixture of triphenylmethanol and an organic solvent; stirring fo...
|
|
WO/2020/243423A1 |
The present invention provides compounds, compositions thereof, and methods of using the same.
|
|
WO/2020/239039A1 |
Disclosed is a novel method for preparing a tetrazine compound. The method uses nitrile and hydrazine hydrate, and can perform various substitutions in the presence of a thiol catalyst to obtain a tetrazine compound with various function...
|
|
WO/2020/243415A2 |
The present invention provides compounds, compositions thereof, and methods of using the same.
|
|
WO/2020/233618A1 |
Provided in the present invention are inhibitors for programmed cell necrosis, a preparation method therefor and a use thereof. Specifically, provided in the present invention are a compound represented by formula I and a composition com...
|
|
WO/2020/223715A1 |
In one aspect, the disclosure relates to compounds useful to regulate, limit, or inhibit the expression of AVIL (advillin), methods of making same, pharmaceutical compositions comprising same, and methods of treating disorders associated...
|
|
WO/2020/210909A1 |
This application relates to compounds of Formula I. R1a, R1b and R1c is –CO2H, –SO2H, –SO3H, –SO4H, –PO2H, –PO3H or –PO4H. R2 is a linker, e.g. butylene. R3 is a linkage, e.g.–O–, –S–, -S(O)-, S(O)2-, –NHC(O)–, ...
|
|
WO/2020/181165A1 |
Provided herein are compounds of formula (I), compositions comprising the compounds and method of treating various diseases with the compounds and compositions.
|
|
WO/2020/154892A1 |
Provided are a preparation method and application of a gadolinium ionic contrast agent intermediate. The method for preparation comprises the following steps: a substance represented by the general formula (II) and a substance represente...
|
|
WO/2020/148175A1 |
The invention relates to acryl carboxamides of the general formula (I) as herbicides. In formula (I) RX, X, Y and Z represent radicals such as alkyl and halogen.
|
|
WO/2020/150210A1 |
The present disclosure relates to compounds of formula (AI), (I), (AII), and (II), or a pharmaceutically acceptable salt, solvate, stereoisomer, or tautomer thereof, a pharmaceutical composition comprising a compound of formula (AI), (I)...
|
|
WO/2020/141723A1 |
The present invention relates to a preparation method for synthesizing highly pure calcobutrol without using highly pure gadobutrol, via the preparation of highly pure butrol through a purification step of butrol which is an intermediate...
|
|
WO/2020/127644A1 |
Bi-functional nanohybridscomprising a nanoparticle to the surface of which are covalently coupledchemical functions, one of which being biorthogonal, and their use as support for catalysts.
|
|
WO/2020/108720A1 |
The present invention relates to novel tetrazine compounds of formula I, wherein one of R1-R5 is 18F, for use in pretargeted in vivo imaging. The compounds are suitable for use in click chemistry, i.e. reactions that join a targeting mol...
|
|
WO/2020/104822A1 |
The present invention relates to a compound of formula (Ia), or a pharmaceutically acceptable salt or hydrate thereof, wherein: the group X-Y is -NHSO2- or -SO2NH-; R1 is H or alkyl; R2 is selected from COOH and a tetrazolyl group; R3 is...
|
|
WO/2020/094999A1 |
The present invention concerns a product characterised in that it has the structure of the following general formula (I): in which R1, R2, R3, R4, Mn+, "Solid support", the bond "~~~" and the bond "¯¯¯¯" between the carbon of the C6H...
|
|
WO/2020/097400A1 |
The present disclosure provides compounds of Formula (I´) (e.g., compounds of Formula (I)), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, cocrystals, tautomers, stereoisomers, isotopically labeled derivatives, a...
|
|
WO/2020/084504A1 |
The present invention relates to an improved process for the preparation of macrocyclic chelant 2,2',2''-(10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecan
e-1,4,7-triyl) triacetic acid of formula (1). The present invention further rela...
|
|
WO/2020/079078A1 |
The present invention relates to compounds Formula (I): wherein R1, R2, R3, R4, R5 and R6 are as defined herein. The invention further relates to compositions comprising said compounds, and methods of controlling weeds using said compoun...
|
|
WO/2020/059841A1 |
The purpose of the invention is to provide a compound which has the effect of suppressing abnormal prion production and is useful as a therapeutic agent for prion diseases. Provided are a compound represented by formula (I) (the symbols ...
|
|
WO/2020/049436A1 |
The present invention relates to a method for the preparation of fluoroalkyl nitrile of Formula I and their use to prepare related fluoroalkyl tetrazole of Formula II in the presence of the dehydrating agent, wherein, x1 and x2 have the ...
|
|
WO/2020/051207A2 |
The disclosure relates to aryl hydrocarbon receptor antagonists as well as methods of modulating aryl hydrocarbon receptor activity and expanding hematopoietic stem cells by culturing hematopoietic stem or progenitor cells in the presenc...
|
|
WO/2020/051206A1 |
Stress responses involve corticotropin releasing factor (CRF), the two cognate receptors (CRFi and CRF 2 ) and the CRF-binding protein (CRFBP). Utilizing a novel cell-based assay, a C-terminal CRFBP fragment [CRFBP(IOkD)] was found to po...
|
|
WO/2020/043866A1 |
A compound for use in the treatment of a disease ameliorated by the inhibition of Notum of formula (I): (I)
|
|
WO/2020/043831A1 |
The present invention relates to compounds of formula (I) or a pharmaceutically acceptable salt thereof useful as inhibitors of Cyclophilins and modulators of cyclophilin-like proteins. The invention also relates to uses of said compound...
|
|
WO/2020/043087A1 |
A method for human serum albumin (HSA) detection in a biological fluid using small molecule, fluorescent compounds having aggregation-induced emission (AIE) characteristics includes contacting the biological fluid with a fluorescent comp...
|
|
WO/2020/040617A1 |
The present invention provides a novel method for producing gadobutrol of high purity or a hydrate thereof. Unlike the conventional method for synthesizing gadobutrol, the production method of the present invention can simplify the proce...
|
